Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 trial of intracerebroventricular 131I-omburtamab for neuroblastoma with CNS or leptomeningeal metastases
jRCT2021200024Phase 3Active, not recruiting
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- May 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
01
Overview
Phase 3, open-label, single-arm trial of 131I-omburtamab in neuroblastoma, Carcinomatous Meningitis (CM) and central nervous system metastases, sponsored by Y-mAbs Therapeutics, Inc. Primary endpoint: Overall survival rate at 3 years. Started May 2021; status: active, not recruiting.
02
Drugs
131I-omburtamab
03
Conditions
neuroblastomaCarcinomatous Meningitis (CM)central nervous system metastases
Beyond the preview
Go deeper on jRCT2021200024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200024.